Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort

Pharmacotherapy

Volumn 32, Issue 3, 2012, Pages 195-201

  Kullar, Ravina ^a   Davis, Susan L ^a,c   Taylor, Thomas N ^a   Kaye, Keith S ^b,d   Rybak, Michael J ^a,b,d  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HENRY FORD HOSPITAL   (United States)

^d DETROIT MEDICAL CENTER   (United States)

Author keywords

Costs and patient outcomes; MRSA bacteremia; Vancomycin consensus guidelines

Indexed keywords

ACICLOVIR; AMINOGLYCOSIDE; COLISTIN; CREATININE; VANCOMYCIN;

ABSCESS; ADULT; ARTICLE; BACTERIAL ARTHRITIS; BACTERIAL ENDOCARDITIS; CATHETER INFECTION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; HOSPITAL COST; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NEPHROTOXICITY; OSTEOMYELITIS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; SKIN INFECTION; TREATMENT DURATION; URINARY TRACT INFECTION; WOUND INFECTION;

ADULT; COHORT STUDIES; DRUG DELIVERY SYSTEMS; FEMALE; HOSPITAL COSTS; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84864609103     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1875-9114.2011.01017.x     Document Type: Article

References (23)

1. Levine DP. Vancomycin: A history. Clin Infect Dis 2006;42 (suppl 1):S5-12.
2. Moellering RC Jr. Vancomycin: A 50-year reassessment. Clin Infect Dis 2006;42(suppl 1):S3-4.
3. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42:2398-402.
4. Moise PA, Schentag JJ. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents 2000;16(suppl 1):S31-4.
5. Rhee KY, Gardiner DF, Charles M. Decreasing in vitro susceptibility of clinical Staphylococcus aureus isolates to vancomycin at the New York Hospital: Quantitative testing redux. Clin Infect Dis 2005;40:1705-6.
6. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 2007;60:788-94.
7. Jones RN. Microbiological features of vancomycin in the 21st century: Minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 2006;42 (suppl 1):S13-24.
8. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004;38:1700-5.
9. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:193-200.
10. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: Efficacy and toxicity. Arch Intern Med 2006;166:2138-44.
11. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52:e18-55.
12. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66:82-98.
13. American Thoracic Society; Infectious Disease Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
14. Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillinresistant Staphylococcus aureus bacteremia: Support for consensus guidelines suggested targets. Clin Infect Dis 2011;52:975-81.
15. Tice AD, Turpin RS, Hoey CT, Lipsky BA, Wu J, Abramson MA. Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infections. Am J Health Syst Pharm 2007;64:1080-6.
16. US Bureau of Labor Statistics. Employer costs for employee compensation. Washington, DC: US Department of Labor., 2008.
17. US Bureau of Labor Statistics. Consumer Price Index, Washington, DC: US Department of Labor. 2009.
18. Mandell GL, Bennett JE, Dolin R. Principles and practice of infectious diseases, 6th ed. Philadelphia: Elsevier Inc, 2005.
19. Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: Reappraisal of their clinical value. Clin Infect Dis 1994;18:533-43.
20. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990;25:679-87.
21. Wong-Beringer A, Joo J, Tse E, Beringer P. Vancomycin-associated nephrotoxicity: A critical appraisal of risk with highdose therapy. Int J Antimicrob Agents 2011;37:95-101.
22. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008;52:1330-6.
23. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillinresistant Staphylococcus aureus pneumonia. Clin Ther 2007;29:1107-15.